GlassScriptPhysician profile
Shahin Mirmanesh
NPI 1679505325
$13,817.92
in general payments reported to CMS, 2019-2025
42 companies · $2,994 in 2025
The $2,994 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,341 · 2020: $1,009 · 2021: $940 · 2022: $1,390 · 2023: $2,246 · 2024: $1,898 · 2025: $2,994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,137.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,160.81 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $1,480.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,236.96 | 2019-2025 | |
| Amgen INC. | $998.79 | 2019-2025 | Repatha, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $708.62 | 2019 | |
| Antares Pharma, INC. | $548.62 | 2022-2025 | Xyosted |
| Glaxosmithkline, LLC. | $546.55 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $503.86 | 2023-2025 | Freestyle Libre 3 |
| Allergan, INC. | $439.44 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $389.74 | 2024-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $356.39 | 2022-2025 | |
| Esperion Therapeutics, INC. | $343.03 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $292.03 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $252.54 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $236.85 | 2019-2025 | Trintellix |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shahin Mirmanesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.